43 research outputs found
Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohnʼs Disease, and Ulcerative Colitis Patients:
Get PDFPrevious studies have demonstrated that serological markers can assist in diagnosing inflammatory bowel disease (IBD). In this study, we aim to build a diagnostic tool incorporating serological markers, genetic variants, and markers of inflammation into a computational algorithm to examine patterns of combinations of markers to (1) identify patients with IBD and (2) differentiate patients with Crohn’s disease (CD) from ulcerative colitis (UC)
999 Classification of non-IBD, Crohn's Disease and Ulcerative Colitis in a Young Patient Population Using a Multi-Marker Diagnostic Panel
No full text1029 Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms
No full text108 Blood MicroRNA (miRNA) Expression Patterns Can Identify Inflammatory Bowel Disease (IBD) Patients With Dysplasia and Cancer
No full textSu1169 Genetic Variants and Markers of Inflammation Help to Identify IBD Patients With Low Serology
No full textMo1322 Serological and Genetic Markers As Predictors of Complicated Disease in Patients With Crohn's Disease
No full text166 Combined Serologic, Genetic, and Inflammatory Markers Can Accurately Differentiate Non-IBD, Crohn's Disease, and Ulcerative Colitis Patients
No full textSa1200 Presence and Concentration of OmpC As a Risk Factor for Developing Antibodies to Infliximab (ATI): Implications for Selecting Patients With Inflammatory Bowel Disease (IBD) for Combination Therapy
No full textA Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease
No full textPrediction of primary non-response [PNR] to anti-tumour necrosis factors [TNFs] in inflammatory bowel disease [IBD] is direly needed to select the optimal therapeutic class for a given patient. We developed a matrix-based prediction tool to predict response to infliximab [IFX] in Crohn's disease [CD] patients.status: publishe
286 Drug Concentrations and Antibodies to Infliximab Are Inferior to the Impact of Disease Burden in Primary Non-Response to Infliximab in Crohn's Disease Patients
No full text
